Shopping Cart
- Remove All
Your shopping cart is currently empty
(9)
By Tag- C-His-Avi
- C-hFc-Myc(1)
- N-10xHis(1)
- N-6xHis(1)
Filter
Applied FilterClear all
By Tag By Expression System- HEK293 Cells(8)
- E. coli(4)
By Species- Human(12)
By SPR-compatible Buffer- Buffer exchange required(6)
- Ready-to-use(6)
Filter
Search Result
Results for "
lage-1
" in TargetMol Product Catalog- Recombinant Protein12
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01500
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01539
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01449
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01546
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareLAGE2B, LAGE2A, LAGE2, L antigen family member 2 (LAGE-2), ESO1, CTAG1B, CTAG1A, CTAG1, CTAG, Cancer testis antigen 6.1 (CT6.1), Cancer testis antigen 1, Autoimmunogenic cancer testis antigen NY-ESO-1
TMPH-01033
Expression system: E. coli
Length: 1-180, Full Length
Activity: Not Tested
Length: 1-180, Full Length
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareLAGE1, L antigen family member 1 (LAGE-1), ESO2, CTAG2, CT2, Cancer testis antigen 6.2 (CT6.2), Cancer testis antigen 2, Autoimmunogenic cancer testis antigen NY-ESO-2
TMPH-04692
CTAG2 Protein, Human, Recombinant (His) is expressed in E. coli. The accession number is O75638.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01513
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01448
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01497
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01499
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareNY-ESO-1, MY-ESO-1, MHC, LAGE2A, LAGE-2, ESO1CTAG, CTAG1B, CTAG1, CT6.1
TMPK-01543
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
- Inquiry Price
Size
QTY
CompareLAGE2B, LAGE2A, LAGE2, L antigen family member 2 (LAGE-2), ESO1, CTAG1B, CTAG1A, CTAG1, CTAG, Cancer testis antigen 6.1 (CT6.1), Cancer testis antigen 1, Autoimmunogenic cancer testis antigen NY-ESO-1
TMPH-01034
Expression system: HEK293 Cells
Length: 1-180, Full Length
Activity: Not Tested
Length: 1-180, Full Length
Activity: Not Tested
- Inquiry Price
Size
QTY
Go to page 1
Page of 1
Product Comparison
| Product |
|---|
| Bioactive |
| Species |
| Expression System |
| Tag |
| Accession Number |
| Amino Acid |
| Construction |
| Molecular Weight |
| Endotoxin |
| Formulation |
| Reconstitution |
| Stability & Storage |
| Shipping |
| Research Background |
| Size |
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.